Sections

Sections Eosinophilic Folliculitis
Overview
Presentation
- History
- Physical
- Causes
- Complications
- Show All
DDx
Workup
Treatment
Medication
Media Gallery
References

Overview

Background

Eosinophilic folliculitis (EF) is a recurrent skin disorder of unknown etiology. In 1965, Ise and Ofuji reported a case of recurrent follicular pustules and eosinophilia in a Japanese woman.^[1]Five years later, and after 3 additional cases, Ofuji named this skin condition eosinophilic pustular folliculitis (EPF).^[2]Orfanos and Sterry argued that the name sterile eosinophilic pustulosis might be more appropriate because this lesion is not restricted to the hair follicle. Other names have also been proposed (eg, classic form of eosinophilic folliculitis, Ofuji disease, eosinophilic pustular dermatosis). Since the 1990s, the spectrum of eosinophilic folliculitis has expanded to pediatric populations, transplant recipients, and persons with HIV and hematopoietic disorders.

Eosinophilic folliculitis is a noninfectious eosinophilic infiltration of hair follicles. The 3 variants of eosinophilic folliculitis include classic eosinophilic pustular folliculitis, immunosuppression-associated eosinophilic folliculitis (mostly HIV-related), and infancy-associated eosinophilic folliculitis.^[3]

Eosinophilic folliculitis has been classified as an AIDS-defining illness. In both children and adults, eosinophilic pustular folliculitis should be viewed as a possible cutaneous sign of immunosuppression. However, eosinophilic folliculitis may also develop in immunocompetent persons.

Eosinophilic pustular folliculitis in a patient infected with HIV. Note acneiform hyperpigmented papules. Photograph courtesy of Sarah A. Myers, MD.

View Media Gallery

Next: Pathophysiology

Pathophysiology

Although the exact etiology of eosinophilic folliculitis remains obscure, studies have favored an autoimmune process directed against sebocytes or some component of sebum. Markers of acute inflammatory activation of the epithelia, such as ICAM-1 and MAC 387, are strongly positive in sebocytes of eosinophilic folliculitis lesions but only weakly reactive in the follicular epithelium. Antibody formation and the creation of immune complexes are believed to directly or indirectly mediate clinical manifestations. Patients with eosinophilic folliculitis create antibodies to the intercellular substance of the lower epidermis and the outer root sheath of the hair follicle. An abnormal Th2-type immune response to a follicular antigen, such as caused by Demodex species, may be responsible for HIV-associated eosinophilic folliculitis.

Members of the interleukin (IL)-36 family, IL-36α, IL-36β and IL-36γ, are potent chemoattractive cytokines for neutrophils and eosinophils.^[4]IL-36 receptor antagonist (IL-36Ra) inhibits IL-36α, IL-36β and IL-36γ activity. However, before the late 1990s, the immunohistological expression of IL-36α, IL-36β, IL-36γ and IL-36Ra had never been addressed in normal follicles, folliculitis or eosinophilic pustular folliculitis (EPF).

Therefore, researchers performed immunohistochemical staining for IL-36α, IL-36β, IL-36γ and IL-36Ra using 10 cases of EPF, nine of non-specific folliculitis, 10 normal skin samples, and 10 samples of normal follicles adjacent to a sebaceous naevus as a control. Two dermatologists, who were blind to the patient records, evaluated all of the slides.

The immunoreactive IL-36α was hardly detected in the follicular epithelium and epidermis in the normal skin, folliculitis or EPF. The expression of IL-36β, IL-36γ and IL-36Ra was augmented in both folliculitis and EPF compared with that in normal follicles. Negative correlations were detected between IL-36β and IL-36Ra and between IL-36γ and IL-36Ra in normal follicles; however, these were absent in folliculitis. In contrast to normal follicles and folliculitis, a significant positive correlation between IL-36β/γ and IL-36Ra was shown in EPF.

The researchers concluded the overexpression of IL-36β, IL-36γ and IL-36Ra is an integral part of the inflammatory response of folliculitis and EPF. The coordinated expression of IL-36γ and IL-36Ra may be related to the pathomechanism of EPF.

Next: Pathophysiology

Epidemiology

Frequency

United States

The prevalence of eosinophilic folliculitis is unknown.

International

The classic form is most closely linked with persons of Japanese descent.^[5]

Mortality/Morbidity

Eosinophilic folliculitis is not disabling or life-threatening, but it may be intensely pruritic.

Race

Eosinophilic folliculitis is more common among Asian persons but also occurs among persons of Hispanic descent and in whites and blacks.

Sex

The male-to-female ratio of eosinophilic folliculitis is 5:1 in all 3 variants.

Classic type eosinophilic folliculitis was found to have no sexual predilection.^[6]

HIV-associated eosinophilic folliculitis is more common among homosexual or bisexual men.

Age

Eosinophilic folliculitis is most common among persons aged 20-40 years.

In the pediatric population, eosinophilic folliculitis typically affects patients aged 5-10 months, although neonatal cases have been reported. A newborn was described with it.^[7]

Next: Pathophysiology

Prognosis

Eosinophilic folliculitis is a benign dermatologic disease; however, eosinophilic folliculitis is associated with advanced AIDS, and patients with HIV infection are at an increased risk of developing opportunistic infections.

Clinical Presentation

Ise S, Ofuji S. Subcorneal pustular dermatosis. A follicular variant?. Arch Dermatol. 1965 Aug. 92(2):169-71. [QxMD MEDLINE Link].
Ofuji S, Ogino A, Horio T, et al. Eosinophilic pustular folliculitis. Acta Derm Venereol. 1970. 50(3):195-203. [QxMD MEDLINE Link].
Nervi SJ, Schwartz RA, Dmochowski M. Eosinophilic pustular folliculitis: a 40 year retrospect. J Am Acad Dermatol. 2006 Aug. 55(2):285-9. [QxMD MEDLINE Link].
Sato S, Chiba T, Nakahara T, Furue M. Upregulation of IL-36 cytokines in folliculitis and eosinophilic pustular folliculitis. Australas J Dermatol. 2020 Feb. 61 (1):e39-e45. [QxMD MEDLINE Link]. [Full Text].
Yamamoto Y, Nomura T, Kabashima K, Miyachi Y. Clinical epidemiology of eosinophilic pustular folliculitis: results from a nationwide survey in Japan. Dermatology. 2015. 230(1):87-92. [QxMD MEDLINE Link].
Lo CS, Yang CY, Ko JH, Lee WY, Shih IH, Lin YC. Hyperimmunoglobulin E syndrome presenting as eosinophilic pustular folliculitis: a case report. Int J Dermatol. 2015 Feb. 54(2):211-4. [QxMD MEDLINE Link].
Yoshida S, Yatsuzuka K, Chigyo K, Kuroo Y, Takemoto K, Sayama K. A Case of Eosinophilic Pustular Folliculitis since Birth. Children (Basel). 2021 Jan 7. 8 (1):[QxMD MEDLINE Link].
Suresh MS, Arora S, Nair RR. Doctor I am on fire: eosinophilic folliculitis in HIV negative. Indian J Dermatol Venereol Leprol. 2009 Mar-Apr. 75(2):194-6. [QxMD MEDLINE Link].
Fraser SJ, Benton EC, Roddie PH, Krajewski AS, Goodlad JR. Eosinophilic folliculitis: an important differential diagnosis after allogeneic bone-marrow transplant. Clin Exp Dermatol. 2009 Apr. 34(3):369-71. [QxMD MEDLINE Link].
Uchiyama M, Mitsuhashi Y, Okubo Y, Tsuboi R. Eosinophilic pustular folliculitis (Ofuji's disease) without macroscopic pustules. Int J Dermatol. 2012 Jan. 51(1):50-2. [QxMD MEDLINE Link].
Scavo S, Magro G, Caltabiano R. Erythematous and edematous eruption of the face. Eosinophilic pustular folliculitis. Int J Dermatol. 2010 Sep. 49(9):975-7. [QxMD MEDLINE Link].
Tsuboi H, Niiyama S, Katsuoka K. Eosinophilic pustular folliculitis (Ofuji disease) manifested as pustules on the palms and soles. Cutis. 2004 Aug. 74(2):107-10. [QxMD MEDLINE Link].
Sufyan W, Tan KB, Wong ST, et al. Eosinophilic pustular folliculitis. Arch Pathol Lab Med. 2007 Oct. 131(10):1598-601. [QxMD MEDLINE Link].
Mizoguchi S, Setoyama M, Higashi Y, Hozumi H, Kanzaki T. Eosinophilic pustular folliculitis induced by carbamazepine. J Am Acad Dermatol. 1988. 38:641-3.
Maejima H, Mukai H, Hikaru E. Eosinophilic pustular folliculitis induced by allopurinol and timedium bromide. Acta DermVenereol. 2002. 82:316-7.
Ooi CG, Walker P, Sidhu SK, Gordon LA, Marshman G. Allopurinol induced generalized eosinophilic pustular folliculitis. Australas J Dermatol. 2006 Nov. 47(4):270-3.
Roos TC, Albrecht H. Foscarnet-associated eosinophilic folliculitis in a patient with AIDS. J Am Acad Dermatol. 2001 Mar. 44(3):546-7.
Laing ME, Laing TA, Mulligan NJ, Keane FM. Eosinophilic pustular folliculitis induced by chemotherapy. J Am Acad Dermatol. 2006 Apr. 54(4):729-30.
Fujii M, Takahashi I, Kishiyama K, Honma M, Ishida-Yamamoto A. Case of generalized eosinophilic pustular folliculitis induced by allopurinol. J Dermatol. 2016 Apr. 43 (4):458-9. [QxMD MEDLINE Link].
Brenner S, Wolf R, Ophir J. Eosinophilic pustular folliculitis: a sterile folliculitis of unknown cause?. J Am Acad Dermatol. 1994 Aug. 31(2 Pt 1):210-2. [QxMD MEDLINE Link].
Veraldi S, Ferrante P, Mancuso R, et al. Evidence of retroviral involvement in an Italian patient with Ofuji's disease. Dermatology. 1999. 198(1):86-9. [QxMD MEDLINE Link].
Gul U, Kilic A, Demiriz M. Eosinophilic pustular folliculitis: the first case associated with hepatitis C virus. J Dermatol. 2007 Jun. 34(6):397-9. [QxMD MEDLINE Link].
Matsudate Y, Miyaoka Y, Urano Y. Two cases of eosinophilic pustular folliculitis associated with pregnancy. J Dermatol. 2016 Feb. 43 (2):218-9. [QxMD MEDLINE Link].
Sugaya M, Suga H, Miyagaki T, Fujita H, Sato S. Eosinophilic pustular folliculitis associated with Sézary syndrome. Clin Exp Dermatol. 2014 Jun. 39(4):536-8. [QxMD MEDLINE Link].
Patrizi A, Chieregato C, Visani G, et al. Leukaemia-associated eosinophilic folliculitis (Ofuji's disease). J Eur Acad Dermatol Venereol. 2004 Sep. 18(5):596-8. [QxMD MEDLINE Link].
Kimoto M, Ishihara S, Konohana A. Eosinophilic pustular folliculitis with polycythemia vera. Dermatology. 2005. 210(3):239-40. [QxMD MEDLINE Link].
Takamura S, Teraki Y. Eosinophilic pustular folliculitis associated with hematological disorders: A report of two cases and review of Japanese literature. J Dermatol. 2016 Apr. 43 (4):432-5. [QxMD MEDLINE Link].
Cunningham F, Gupta P, Becher G, Magro CM. Necrotizing eosinophilic folliculitis: a new manifestation of the atopic diathesis?. Clin Exp Dermatol. 2017 Jan. 42 (1):100-101. [QxMD MEDLINE Link].
Jiang YY, Zeng YP, Jin HZ. Eosinophilic Pustular Folliculitis Associated with Cutaneous Angiosarcoma. Chin Med J (Engl). 2018 Jan 5. 131 (1):115-116. [QxMD MEDLINE Link].
Owen RL, Shah KK, Sosis AC, Purcell SM. Eosinophilic pustular folliculitis with underlying mantle cell lymphoma. Cutis. 2018 Jun. 101 (6):454-457. [QxMD MEDLINE Link].
Goiriz R, Guhl-Millan G, Penas PF, et al. Eosinophilic folliculitis following allogeneic peripheral blood stem cell transplantation: case report and review. J Cutan Pathol. 2007 Dec. 34 Suppl 1:33-6. [QxMD MEDLINE Link].
Kim BW, Lee JH, Won CH, Chang SE, Lee MW, Choi JH, et al. Eosinophilic pustular folliculitis: association with long-term immunosuppressant use in a solid organ transplant recipient. Ann Dermatol. 2014 Aug. 26(4):520-1. [QxMD MEDLINE Link]. [Full Text].
Chuh A. Eosinophilic folliculitis due to wearing protective gear in citizens volunteering for sanitation services during the COVID-19 pandemic - an original epidemiological, clinical, dermoscopic, and laboratory-based study. Int J Dermatol. 2020 Dec. 59 (12):1468-1474. [QxMD MEDLINE Link].
Fujiyama T, Tokura Y. Clinical and histopathological differential diagnosis of eosinophilic pustular folliculitis. J Dermatol. 2013 Jun. 40(6):419-23. [QxMD MEDLINE Link].
Takashima S, Nishie W, Morita Y, Osawa R, Iwata H, Fujita Y, et al. Eosinophilic pustular folliculitis in a patient with mycosis fungoides. J Eur Acad Dermatol Venereol. 2015 Feb 11. [QxMD MEDLINE Link].
Chopra D, Kumari S, Kundal RK, Bahl RK, Aggarwal S, Singh H, et al. A study of clinicopathological correlation of pruritic papular eruptions in HIV patients. Indian J Sex Transm Dis AIDS. 2018 Jan-Jun. 39 (1):44-49. [QxMD MEDLINE Link].
Boone SL, Guitart J, Gerami P. Follicular mycosis fungoides: a histopathologic, immunohistochemical, and genotypic review. G Ital Dermatol Venereol. 2008 Dec. 143(6):409-14. [QxMD MEDLINE Link].
Schwartz RA, Janniger CK. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Dermatol Ther. 2020 May. 33 (3):e13380. [QxMD MEDLINE Link].
Fertitta, Laura; Bodemer, Christine; Molina, Thierry; Frassati-Biaggi, Annonciade; Fraitag, Sylvie; Leclerc-Mercier, et al. Eosinophilic Pustular Folliculitis of Infancy: A Histologic Assessment of 43 Cases. A J Derm. June 2022. 44(6):395-403(9). [Full Text].
Piantanida EW, Turiansky GW, Kenner JR, Mather MK, Sperling LC. HIV-associated eosinophilic folliculitis: Diagnosis by transverse histologic sections. J Am Acad Dermatol. 1998 Jan. 38(1):124-6.
Junqueira Magalhães Afonso JP, Tomimori J, Michalany NS, Nonogaki S, Porro AM. Pruritic papular eruption and eosinophilic folliculitis associated with human immunodeficiency virus (HIV) infection: A histopathological and immunohistochemical comparative study. J Am Acad Dermatol. 2012 Apr 19. [QxMD MEDLINE Link].
Satoh T, Ito Y, Miyagishi C, Yokozeki H. Basophils Infiltrate Skin Lesions of Eosinophilic Pustular Folliculitis (Ofuji's Disease). Acta Derm Venereol. 2011 Jan 31. [QxMD MEDLINE Link].
Patel NP, Laguda B, Roberts NM, Francis ND, Agnew K. Treatment of Eosinophilic Pustulosis of Infancy with Topical Tacrolimus. Br J Dermatol. 2012 May 7. [QxMD MEDLINE Link].
Ng SS, Tay YK. Successful treatment of eosinophilic pustular folliculitis with topical tacrolimus 0.1 percent ointment. Dermatol Online J. 2012 Feb 15. 18(2):10. [QxMD MEDLINE Link].
Toyonaga E, Abe R, Moriuchi R, Ito K, Abe Y, Shimizu H. Indomethacin for refractory infantile eosinophilic pustular folliculitis. JAMA Dermatol. 2013 Mar. 149(3):367-8. [QxMD MEDLINE Link].
Nomura T, Katoh M, Yamamoto Y, Miyachi Y, Kabashima K. Eosinophilic pustular folliculitis: A published work-based comprehensive analysis of therapeutic responsiveness. J Dermatol. 2016 Aug. 43 (8):919-27. [QxMD MEDLINE Link]. [Full Text].
Fukamachi S, Kabashima K, Sugita K, Kobayashi M, Tokura Y. Therapeutic effectiveness of various treatments for eosinophilic pustular folliculitis. Acta Derm Venereol. 2009. 89(2):155-9. [QxMD MEDLINE Link].
Otsuka A, Doi H, Miyachi Y, Kabashima K. Treatment of eosinophilic pustular folliculitis with ciclosporin: suppression of mRNA expression of IL-4 and IL-13. J Eur Acad Dermatol Venereol. 2010 Dec. 24(12):1489-91. [QxMD MEDLINE Link].
Annam V, Yelikar BR, Inamadar AC, Palit A, Arathi P. Clinicopathological study of itchy folliculitis in HIV-infected patients. Indian J Dermatol Venereol Leprol. 2010 May-Jun. 76(3):259-62. [QxMD MEDLINE Link].
Dwivedi M, Sharma V, Pathak K. Pilosebaceous targeting by isotretenoin-loaded invasomal gel for the treatment of eosinophilic pustular folliculitis: optimization, efficacy and cellular analysis. Drug Dev Ind Pharm. 2017 Feb. 43 (2):293-304. [QxMD MEDLINE Link].
Inaoka M, Hayakawa J, Shiohara T. HIV seronegative eosinophilic pustular folliculitis successfully treated with metronidazole. J Am Acad Dermatol. 2002 May. 46(5 Suppl):S153-5.
Lim HW, Vallurupalli S, Meola T, et al. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol. 1997 Sep. 37(3 Pt 1):414-7. [QxMD MEDLINE Link].
Misago N, Narisawa Y, Matsubara S, et al. HIV-associated eosinophilic pustular folliculitis: successful treatment of a Japanese patient with UVB phototherapy. J Dermatol. 1998 Mar. 25(3):178-84. [QxMD MEDLINE Link].
Hara D, Kuroda K, Mieno H, et al. Treatment of eosinophilic pustular folliculitis with tacrolimus ointment. J Am Acad Dermatol. 2004 Nov. 51(5 Suppl):S143-5. [QxMD MEDLINE Link].
Kabashima K, Sakurai T, Miyachi Y. Treatment of eosinophilic pustular folliculitis (Ofuji's disease) with tacrolimus ointment. Br J Dermatol. 2004 Oct. 151(4):949-50. [QxMD MEDLINE Link].
Kawaguchi M, Mitsuhashi Y, Kondo S. Successful treatment of eosinophilic pustular folliculitis with topical tacrolimus. Int J Dermatol. 2004 Aug. 43(8):608-10. [QxMD MEDLINE Link].
Brazzelli V, Barbagallo T, Prestinari F, et al. HIV seronegative eosinophilic pustular folliculitis successfully treated with doxicycline. J Eur Acad Dermatol Venereol. 2004 Jul. 18(4):467-70. [QxMD MEDLINE Link].
Wilson BD, Kucera JC, Shin PJ. The role of radiation treatment in the management of eosinophilic pustular folliculitis. J Med. 2002. 33(1-4):111-3. [QxMD MEDLINE Link].
Odyakmaz Demirsoy E, Demirsoy U, Ozod U, Kiran R. Eosinophilic pustular folliculitis of infancy suppressed with cetirizine. Pediatr Dermatol. 2019 Feb 21. [QxMD MEDLINE Link].
Ishiguro N, Shishido E, Okamoto R, Igarashi Y, Yamada M, Kawashima M. Ofuji's disease: A report on 20 patients with clinical and histopathologic analysis. J Am Acad Dermatol. 2002 Jun. 46(6):827-33.
Ramondetta A, Giuffrida G, Di Vincenzo S, De Pasquale R. A case of eosinophilic pustular folliculitis successfully treated with adalimumab. Dermatol Ther. 2022 May 4. e15550. [QxMD MEDLINE Link].
Bürgler C, Guillet C, Kolm I, Theiler M, Schmid-Grendelmeier P, Kroiss S, et al. Treatment of eosinophilic pustular folliculitis with benralizumab in a 13-year-old girl. J Eur Acad Dermatol Venereol. 2021 Feb 17. [QxMD MEDLINE Link].
Satoh T, Shimura C, Miyagishi C, Yokozeki H. Indomethacin-induced reduction in CRTH2 in eosinophilic pustular folliculitis (Ofuji's disease): a proposed mechanism of action. Acta Derm Venereol. 2010. 90(1):18-22. [QxMD MEDLINE Link].
Nomura T, Katoh M, Yamamoto Y, Miyachi Y, Kabashima K. Eosinophilic pustular folliculitis: Trends in therapeutic options. J Dermatol. 2016 Feb 15. [QxMD MEDLINE Link].
Nomura T, Katoh M, Yamamoto Y, Miyachi Y, Kabashima K. Eosinophilic pustular folliculitis: A proposal of diagnostic and therapeutic algorithms. J Dermatol. 2016 Mar 30. [QxMD MEDLINE Link].
Dong RJ, Huang SZ, Upadhyay P, Shrestha S, Zhai YJ, Li YY. Thalidomide in the Treatment of Sweet's Syndrome and Eosinophilic Folliculitis Associated With Immune Reconstitution Inflammatory Syndrome. Front Med (Lausanne). 2019. 6:343. [QxMD MEDLINE Link].
Hernández-Martín Á, Nuño-González A, Colmenero I, Torrelo A. Eosinophilic pustular folliculitis of infancy: a series of 15 cases and review of the literature. J Am Acad Dermatol. 2013 Jan. 68 (1):150-5. [QxMD MEDLINE Link].
Hernández-Martín Á, Nuño-González A, Colmenero I, Torrelo A. Eosinophilic pustular folliculitis of infancy: a series of 15 cases and review of the literature. J Am Acad Dermatol. 2013 Jan. 68 (1):150-5. [QxMD MEDLINE Link].
Tan X, Nie S, Chen B, Wu Z. Successful Treatment of Eosinophilic Pustular Folliculitis With Dupilumab in a 9-Year-Old Boy. Pediatr Dermatol. 2025 Mar 6. [QxMD MEDLINE Link]. [Full Text].
Cai L, Yan Y, Li Y, Lin J, She X, Wang X. Two cases of eosinophilic pustular folliculitis successfully treated with abrocitinib. J Dermatol. 2024 Dec. 51 (12):1694-1697. [QxMD MEDLINE Link]. [Full Text].
Chersi F, Zelin E, Mazzoletti V, Caro Caposiena DR, Hasa Z, Nan K, et al. Mepolizumab therapy for eosinophilic pustular folliculitis (Ofuji disease). J Eur Acad Dermatol Venereol. 2024 Nov. 38 (11):e993-e996. [QxMD MEDLINE Link]. [Full Text].
Curkovic NB, Yuan IH, Bahrani E, Keefe MS, Kahwash BM. Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia. JAAD Case Rep. 2024 Nov. 53:43-46. [QxMD MEDLINE Link]. [Full Text].
Wang QX, He HY, Niu YL, Fang S. Refractory eosinophilic pustular folliculitis treated with tofacitinib: a case series and literature review. Clin Exp Dermatol. 2025 Feb 1. [QxMD MEDLINE Link]. [Full Text].
Zheng C, Yu Y, Zhou G, Liu H. A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor. J Dermatolog Treat. 2024 Dec. 35 (1):2331785. [QxMD MEDLINE Link]. [Full Text].

Media Gallery

Eosinophilic pustular folliculitis in a patient infected with HIV. Note acneiform hyperpigmented papules. Photograph courtesy of Sarah A. Myers, MD.
Eosinophilic pustular folliculitis in a patient who is HIV-positive. Note follicular-based excoriated papules and pustules on the trunk. Photograph courtesy of Sarah A. Myers, MD.
Eosinophilic folliculitis (low-power). Note eosinophilic spongiosis, particularly involving the infundibular region of the hair follicle.
Eosinophilic folliculitis (high-power). In addition to the abundant eosinophils, note the variable numbers of neutrophils and mononuclear cells.

of 4

#author-disclosures{display:block}#author-disclosures.modal-layer{position:relative}#author-disclosures .modal-content{max-height:none}#author-disclosures .close-modal{display:none}

Author

Camila K Janniger, MD Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, Rutgers New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Coauthor(s)

M Angelica Selim, MD, MD Director of Dermatopathology, Departments of Pathology and Internal Medicine, Associate Professor, Duke University Medical Center

Disclosure: Nothing to disclose.

Christopher R Shea, MD Eugene J Van Scott Professor in Dermatology, Chief, Section of Dermatology, Department of Medicine, University of Chicago, The Pritzker School of Medicine

Christopher R Shea, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society of Dermatopathology, Arthur Purdy Stout Society, Association of Professors of Dermatology, Chicago Dermatological Society, Dermatology Foundation, Illinois Dermatological Society, International Society of Dermatopathology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Joseph F John, Jr, MD, FACP, FIDSA, FSHEA Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina College of Medicine; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center

Joseph F John, Jr, MD, FACP, FIDSA, FSHEA is a member of the following medical societies: Charleston County Medical Association, Infectious Diseases Society of America, South Carolina Infectious Diseases Society

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Rajendra Kapila, MD, MBBS † Professor, Department of Medicine, Rutgers New Jersey Medical School

Rajendra Kapila, MD, MBBS is a member of the following medical societies: American College of Physicians, American Medical Association, Infectious Diseases Society of America, Infectious Diseases Society of New Jersey

Disclosure: Nothing to disclose.

Harry Dao, Jr, MD Assistant Professor, Department of Dermatology, Baylor College of Medicine

Harry Dao, Jr, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

TOP PICKS FOR YOU

Sections Eosinophilic Folliculitis
Overview
Presentation
- History
- Physical
- Causes
- Complications
- Show All
DDx
Workup
Treatment
Medication
Media Gallery
References

Eosinophilic Folliculitis

Background

Pathophysiology

Epidemiology

Frequency

Mortality/Morbidity

Race

Sex

Age

Prognosis

References

Tables

Contributor Information and Disclosures

What would you like to print?